RxDoctor Payments Data

Emil Fernando, MD

Internal Medicine · Poplar Bluff, MONPI 1982968129

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 45 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$248
  • GSK$123
  • Otsuka America Pharmaceutical, Inc.$123
  • Novo Nordisk$115
  • Johnson & Johnson$106
  • Bayer$97
  • plus $442 from 11 others

What the payments were for

  • Food & beverage$1,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$79,481
Medicare patients
232
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$112,852
XareltoRivaroxaban41$38,845
Semglee (Yfgn) PenInsulin Glargine-Yfgn77$36,165
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$33,193
TrulicityDulaglutide22$27,989
OzempicSemaglutide14$19,230
ProliaDenosumab11$19,010
MyrbetriqMirabegron25$17,621
JanuviaSitagliptin Phosphate15$16,699
Breo ElliptaFluticasone/Vilanterol28$12,313
Incruse ElliptaUmeclidinium Bromide11$6,578
EntrestoSacubitril/Valsartan18$6,383
Mirabegron ErMirabegron13$6,082
ArexvyRsvpref3 Antigen/As01e/Pf22$6,077
Atorvastatin Calcium424$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$123$58,16199 claims
Johnson & JohnsonXarelto$106$38,84541 claims
Lilly USA, LLCTrulicity$64$27,98922 claims
Novo NordiskOzempic$115$19,23014 claims
Astellas Pharma US IncMyrbetriq$32$17,62125 claims
NovartisEntresto$16$6,38318 claims
Almatica Pharma LLCSertraline Hcl$41$1,717155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Poplar Bluff

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →